CSIMarket
 



Shattuck Labs Inc   (STTK)
Other Ticker:  
 
 



 

What are Shattuck Labs Inc's Business Segments?



Shattuck Labs Inc is a clinical-stage biotechnology company that focuses on developing and commercializing innovative therapeutics for the treatment of cancer and autoimmune diseases. The company has developed several segments, products, and services to address the needs of patients suffering from these diseases.

Segments:
Shattuck Labs focuses its business on two main segments:

1. Oncology: This segment is devoted to developing cancer treatments that can help patients in need. The oncology segment is divided into further sub-segments according to the modality of action of the product.

a. Fusion Protein Platform: This platform is designed to engineer a cytokine (interleukin-2) to selectively target activated immune cells to fight cancer cells, utilizing Shattuckes proprietary fusion protein technology. The platform allows local dosing, which avoids the toxic side effects associated with systemic cytokine infusion, and increases the specificity of activation in the tumor microenvironment.

b. Agonist Redirected Checkpoint (ARC) Platform: This proprietary platform is designed to develop a new class of tumor-targeted immunotherapies. ARCs are designed to redirect immune cells to engage the checkpoint molecules expressed by cancer cells, exploiting the checkpoint pathwayes regulatory function in cancer.

c. Bispecific Fusion Protein Technology: Bispecific fusion proteins are designed to engage multiple immune cells and activate them to potentiate the anti-tumor response in cancer patients.

2. Autoimmune Diseases: This segment is devoted to delivering therapeutics to help alleviate the suffering of patients with autoimmune diseases. The segment includes products like:

a. PD-1xCTLA-4 Bispecific Antagonist: This product is designed to harness the power of the immune system to fight autoimmune diseases.

Products:
Shattuck Labs Inc offers a variety of products that aim to bring relief to patients suffering from cancer and autoimmune diseases. Some of their products are:

1. SL-172154: SL-172154 is a cytokine-fusion protein that selectively targets activated immune cells to fight cancer cells in the tumor microenvironment. The drug is currently in phase I of clinical trials.

2. SL-279252: SL-279252 is an agonist-redirected checkpoint (ARC) that can generate a series of new checkpoint inhibitors with characteristics that make them more effective against tumors. The drug is currently in the preclinical stage of development.

3. SL-15252: SL-15252 is a bispecific fusion protein aimed at potentiate the immune system of cancer patients. The drug is currently in the preclinical stage.

Services:
Shattuck Labs offers a range of services that cater to the requirements of patients suffering from cancer and autoimmune diseases. These services include:

1. Clinical Trials: Shattuck Labs has a robust clinical trial program that focuses on developing treatments in various cancer types and autoimmune diseases.

2. Health Care Providerse Services: Shattuck Labs provides healthcare providers with a range of services, including educational resources, treatment plans, and access to clinical experts in the field.

3. Patient Care Services: Shattuck Labs Inc offers various patient care services, such as patient support programs, that help to improve the quality of life of patients suffering from cancer and autoimmune diseases.

In conclusion, Shattuck Labs Inc has developed a range of segments, products, and services to bring relief to patients suffering from cancer and autoimmune diseases. The companyes innovative therapies aim to harness the body's immune system to fight diseases and help patients live a better and healthier life.
   

Shattuck Labs Inc Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q3
Revenues
(in millions $)
Q3
Income
(in millions $)
(Sep 30 2023)
%
(Profit Margin)
Total 0.69 -27.54 -

Growth rates by Segment Q3
Y/Y Revenue
%
(Sep 30 2023)
Q/Q Revenue
%
Q3
Y/Y Income
%
(Sep 30 2023)
Q/Q Income
%
Total 223.58 % 243 % - -

To get more information on Shattuck Labs Inc's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com